1. Home
  2. FBIN vs COGT Comparison

FBIN vs COGT Comparison

Compare FBIN & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fortune Brands Innovations Inc.

FBIN

Fortune Brands Innovations Inc.

HOLD

Current Price

$51.32

Market Cap

6.2B

ML Signal

HOLD

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

HOLD

Current Price

$36.37

Market Cap

6.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FBIN
COGT
Founded
1988
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Building Products
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.2B
6.5B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
FBIN
COGT
Price
$51.32
$36.37
Analyst Decision
Hold
Buy
Analyst Count
9
14
Target Price
$62.13
$32.08
AVG Volume (30 Days)
2.8M
1.8M
Earning Date
02-12-2026
02-27-2026
Dividend Yield
2.03%
N/A
EPS Growth
N/A
N/A
EPS
2.47
N/A
Revenue
$4,463,200,000.00
N/A
Revenue This Year
$5.53
N/A
Revenue Next Year
$4.63
N/A
P/E Ratio
$20.82
N/A
Revenue Growth
N/A
N/A
52 Week Low
$44.04
$3.72
52 Week High
$70.05
$43.73

Technical Indicators

Market Signals
Indicator
FBIN
COGT
Relative Strength Index (RSI) 38.51 45.95
Support Level $53.30 $35.50
Resistance Level $62.26 $38.19
Average True Range (ATR) 2.47 1.72
MACD -0.37 -0.16
Stochastic Oscillator 8.89 20.96

Price Performance

Historical Comparison
FBIN
COGT

About FBIN Fortune Brands Innovations Inc.

Fortune Brands Innovations is a leading home and security products company that has three reportable segments. The company's $2.6 billion water segment, led by the Moen brand, sells faucets, showers, and other plumbing fixtures; the $1.4 billion outdoors segment primarily sells entry doors under the Therma-Tru brand name and Fiberon-branded patio decking; and the $700 million security segment sells locks and other security devices under the Master Lock, SentrySafe, Yale, and August brand names.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: